CS Paper Radar

RECITE: Revising Eligibility Criteria Incorporating Textual Evidence

Russell Ro, Reza Abbasi-Asl

cs.AI ·submitted 2026-10-30 07:34 UTC · v1
top venuebenchmark

Abstract

Overly restrictive eligibility criteria contribute to widespread enrollment failure in clinical trials, yet published recommendations for how specific criteria should be broadened remain disconnected from trial design at scale. We introduce RECITE (Revising Eligibility Criteria Incorporating Textual Evidence), a framework for automated discovery, extraction, and implementation of evidence-based eligibility criteria revisions. RECITE uses protocol amendment documents from ClinicalTrials.gov to construct a dataset of 11,913 curated instances across 5,735 trials, each pairing original criteria with documentary evidence and target revisions. We benchmark fifteen LLM configurations under truncated-to-context-window and retrieval-augmented generation conditions, on a 3,116-instance sample under an LLM-as-judge protocol validated against ten domain experts (judge vs. human quadratic-weighted Cohen's $κ_{qw} = 0.694 \pm 0.096$). The best open-weight model, Gemma 2 9B, achieves $κ_{qw}$-aligned ordinal score $3.0 \pm 0.9$ on a 0--4 scale (normalized 0.742) and the best closed-weight model, GPT-4o, reaches $3.0 \pm 0.8$ (normalized 0.745). Using an agentic literature discovery system, we then identified 44 paper--trial matches across five publications providing trial-design and EC-modification evidence. Our findings suggest that existing clinical knowledge can be operationalized into actionable trial design recommendations.

Comment
18 pages, 4 figures, 4 tables. Extended version of a paper in KDD 2026 (32nd ACM SIGKDD Conference on Knowledge Discovery and Data Mining). Code and data: https://doi.org/10.5281/zenodo.20487342
DOI
10.1145/3770855.3819027

Closest papers

Nearest neighbours by meaning across the whole index.

TrialJev: Open-Weight Single Pass Eligibility Scoring for Patient Trial Screening

cs.LG ·2026-11-06 ·Omar Ibrahim, Grant Hamblin, Benjamin Haibe-Kains
code/data similarity 0.71
Abstract · 38 pages. Code: https://github.com/oibrahi1/TrialJev. Models: https://huggingface.co/omareng/TrialJev

Clinical trial screening requires assessing large numbers of patient-trial pairs to prioritize candidates for detailed eligibility review, often under restrictions on sharing patient records. We introduce TrialJev, an open-weight eligibility scorer that uses LoRA-adapted Qwen models and a pointer head to score natural-language answer options in a single forward pass, without autoregressive decoding. Trained on TREC Clinical Trials 2021 and evaluated on 6,975 eligible-or-excluded pairs from 50 unseen TREC 2022 synthetic patients, TrialJev achieves 80.97% (Qwen3.5-27B) and 81.84% (Qwen3.8-27B) accuracy, compared with 79.87% and 79.93% for LLMs fine-tuned on the same data to generate verdicts. In matched batch-1 measurements, verdict generation takes 2.45-2.70 times as long as the one-pass inference of TrialJev at 9B-27B. Under a common development-fitted decision correction, the two 27B TrialJev models reach 80.99% and 81.88% accuracy, compared with 81.28% for the proprietary hosted Jev API; paired confidence intervals include zero. TrialJev runs locally on a single GPU, requiring approximately 178 ms per pair at 27B, without transmitting patient text to an external model API. An A/B-logit ablation shows that avoiding decoding, rather than the pointer head alone, accounts for the measured efficiency advantage. TrialJev is intended for first-pass prioritization of candidate trials, complementing rather than replacing explanatory models and clinical review. Evaluation is limited to synthetic patients and implementation-specific timing, and clinical use has not been validated. Adapters, pointer heads, and model cards are released on Hugging Face.

0.22

TrialDesignBench: Benchmarking Language Models for Phase-I Trial Design Against Clinical Knowledge

cs.AI cs.CLstat.AP ·2026-11-09 ·Yihan Hank Tang, Peng Yang, Jiayi Xin, Tianqi Shang, Xuyang Chen +3 more
publishedbenchmarkcode/data similarity 0.66
Abstract · 13 pages, 3 figures, 6 tables. Presented as a poster at the NeurIPS 2026 Workshop on World Models for High-Stakes Health (WMHS). Code and da…

AI is used in much of the clinical trial pipeline. However, selecting the statistical design of a trial, a crucial step that determines how drug doses are tested on humans and evaluated, has seen almost no AI progress. LLMs appear to be a natural fit given their strengths in biomedical knowledge and statistical reasoning. Nevertheless, there is currently no appropriate way to evaluate such abilities because recent regulatory and methodological shifts, most notably FDA's Project Optimus, have redefined what constitutes a reasonable design and rendered many previous designs obsolete. To lay the groundwork for AI-assisted trial design, we introduce TrialDesignBench, a benchmark of 617 Phase-I/I-II oncology dose-finding trials, each paired with an expert-validated reference design that is consistent with the latest FDA regulatory initiatives. This reference standard is produced through a formalization of the expert design process. We evaluate five frontier LLMs, none of which matches the reference standard. Our ablation experiments trace this performance gap to two main causes, inference of latent, unrecorded design determinants from trial sources (supplying them raises class-wise balanced accuracy by 0.22) and structured decision-tree reasoning (+0.24). TrialDesignBench offers a reproducible, contemporary-standard objective for evaluating and enhancing AI-assisted trial design.

0.56

Grounded Adjudication of Variations across Extracted TimeLines (GAVEL): Comparing Clinical Timelines Against Their Case Reports

cs.AI ·2026-09-11 ·Jack Cummins, Sayantan Kumar, Ketan Tamirisa, Jeremy C. Weiss
similarity 0.66
Abstract · AMIA Informatics Summit 2027

Existing pipelines for clinical timeline extraction from case reports are evaluated using an expert reference and are limited by imperfect reference annotations and imprecise event alignment. We developed GAVEL, an LLM judge protocol that compares two timelines with the case report and returns a discrepancy type, verdict, and report passage for each difference. We evaluated the event matcher, reviewed 2,738 findings from GPT5.6sol and DeepSeek V3.2, ranked six LLM extractors and two human annotators, and tested GAVEL guided merging. True match rates were 60% immediately below and 48% immediately above the 0.10 cutoff. Manual review confirmed 89.4% and 88.6% of findings. Across 126 reports, merged timelines were preferred in 77.0% of comparisons (95% CI, 69.8 to 84.1%) and reduced discrepancies attributed to the evaluated timeline from 7.63 to 0.85 per report. GAVEL supports report-based comparison and revision without treating either timeline as ground truth.

0.27

How Ground Truth Shapes Retrieval Scores: Evidence-Aware Evaluation of a Retrieval-Augmented Generation System for Breast Lesions

cs.CL cs.AI ·2026-10-22 ·Miguel Mochizuki Silva, Samuel Ismael, Mateus C. Dias, Thaís Gaudêncio, Yuri Malheiros +1 more
benchmark similarity 0.66
Abstract · 18 pages, 3 figures, 6 tables

Purpose: To describe an evidence-aware retrieval evaluation protocol for a clinical retrieval-augmented generation (RAG) system over breast lesion management literature, addressing the dependence of retrieval scores on annotation coverage. Methods: An 18-document corpus and an 18-query development benchmark, with one Yes/No or WH-question per document, were used. Retrieval combined dense embeddings, BM25, and cross-encoder reranking. Chunk sizes of 128 to 1024 tokens, overlaps of 0 to 20%, and four retriever configurations were evaluated. Relevance was defined by evidence spans mapped to all containing chunks, treating overlapping chunks with equivalent evidence as relevant. Retrieval was evaluated using R-Precision, Recall@K, MRR, and nDCG@K. Separately, generation was assessed on a 512-token index at K=1 to 5 using DeepEval claim-level metrics, with deepseek-v4-pro as the LLM judge, and BLEU/ROUGE metrics. Results: The selected hybrid retriever, using 384-token chunks and 20% overlap, retrieved accepted evidence in the top three results for 17 of 18 queries. Recall@3, R-Precision, MRR@3, and nDCG@3 each reached 0.94. Ground-truth curation increased evidence spans from 25 to 37 and accepted chunk targets from 36 to 51 without changing retrieval rankings. Conclusion: Cross-encoder reranking achieved the highest retrieval scores. Expanded relevance annotations increased recognized evidence without changing rankings, highlighting annotation sensitivity. The small development set and retrieval-informed curation require independent validation, including radiologist assessment of evidence sufficiency.

0.27

Auditable Clinical Timeline Reconstruction with Provenance-Aware Evidence Graphs

cs.AI ·2026-10-05 ·Judith Jeyafreeda Andrew
similarity 0.65
Abstract · 30 pages, 11 Tables, 6 figures

A patient-timeline reconstruction system is auditable only if it keeps the mentions behind each answer, records how facts were revised, and declines to answer when the evidence is not in the text. This study tests these three properties on a fully synthetic corpus (1,000 patients, 3,353 notes, 220 revision edges). Two provenance-aware Evidence Graph operators reduced the node-plus-edge count to 67% and 63% (77-78% of serialized size) while preserving every answer and mention link across 6,813 query points answerable by recency; a fixed-window baseline returned no value for 53.4% of points, unflagged. On evidence-unavailable controls that announce the omission, a BioClinicalBERT gate and a zero-shot LLM gate responded mainly to the announcement. On marker-free controls, BERT abstained on 0 of 81 notes while its accuracy fell from 93.8% to 59.3% across all three relation classes; the LLM's coverage fell from 75.6% to 27.7% on notes its own model family judged undeterminable. Against 482 regenerated gold spans, the LLM's cited evidence reached recall 0.850 and precision 0.864; BERT's span head, trained without span labels, did not localize evidence. A temporally versioned provenance graph stored abstentions as typed, queryable edges. The clean task admits a 0.651-accuracy shortcut, and results describe implementation behaviour on synthetic data, not clinical performance.

0.11

Temporal Evidence Allocation For Longitudinal Clinical Retrieval: A Position And Technical Report

cs.AI ·2026-10-20 ·Soumya Ranjan Sahoo, Divya Bharti, Sanand Sasidharan
publishedposition similarity 0.65
Abstract · Extended report of our accepted abstract at IEEE BHI 2026

Electronic health records are written to support care, not retrieval. Across years of oncology notes, the primary diagnosis is restated in report after report, while the events that shape a patient's course, such as a recurrence or a change in therapy, may be recorded only once. A retriever that ranks passages by similarity to the query keeps returning the repeated material and can miss these transitions, that is, it exhibits temporal redundancy across historical narratives. We argue that longitudinal clinical retrieval should be treated as allocating a limited evidence budget across time, not just ranking by relevance. We separate the task into three objectives: temporal evidence allocation, candidate reconstruction, and clinical validation. In Study A (13 clinical queries over 20 patient records, with two-stage reconstruction), the Temporal-15 configuration reaches a milestone slot recall of 0.538, compared with 0.388 for the Global-50 baseline. However, it also retrieves far more evidence (496 versus 50 indexed units per query), so the gain cannot be credited to allocation alone. When evidence is held fixed, removing prompted precedence rules raises schema-order reversals from 0.010 to 0.080. A five-patient, single-query pilot with fixed budgets finds that wider temporal coverage does not reliably yield more dated milestones. Together, these results suggest that how much a record says about a period is a poor guide to how useful that period is as evidence. Because no expert reference timelines are available, our measurements describe retrieval behavior rather than clinical accuracy. This position and technical report presents the retrieval analysis behind the Onco-CONSTRUE framework and sets out a research agenda for budget-constrained longitudinal clinical retrieval.

0.29

Answering clinicians' questions over trial evidence tables with verifiable, feedback-driven language models

cs.AI ·2026-10-01 ·Manan Roy Choudhury, Suparno Roy Chowdhury, Swastik Sahoo, Muhammad Ali Khan, Kaneez Zahra Rubab Khakwani +3 more
published similarity 0.64
Abstract

Systematic reviews condense clinical trials into evidence tables, yet clinicians can interrogate these tables only through database queries, and many questions concern attributes that the table does not record, such as a drug's target class or a harmonised endpoint. Here we introduce FD-SCoPE, a language-model framework that answers both kinds of question, exposes the query, the selected trials and the derivation rule behind every answer, and learns from expert corrections. On an oncology evidence table of 159 immune checkpoint inhibitor trial records, FD-SCoPE completed all 140 clinician-style tasks (alternatives, 90.7-97.9%). For questions needing derived attributes it retrieved 99.3% of relevant trial records at a positive predictive value of 89.8% and outperformed four alternative approaches (derived-value F1 77.7% versus 64.8-73.4%). Corrections on 299 questions, simulated from reference answers, raised F1 on 1,201 unseen questions from 77.9% to 84.9%. Language models coupled with executable queries, verified programs and expert feedback can give clinicians auditable access to trial evidence.

0.32

Can JEV Support Clinical Trial Criteria Assessment?

cs.LG cs.AIcs.CL ·2026-10-26 ·Mengxian He, Ziyue Gao, Chun Li, Shunyi Zhang, Hao Wei +2 more
hot direction similarity 0.64
Abstract

Clinical trial prescreening requires distinguishing unmet conditions from insufficient evidence in patient records. Given patient records, criterion questions, and predefined answer options, we retrospectively compared JEV, a non-generative decision model returning native option probabilities, with schema-constrained Qwen Flash across 2,048 test patient-condition pairs from TrialGPT and question-answer datasets derived from MIMIC-III and MIMIC-IV, all evaluated under strict Zero Data Retention (ZDR) policies to ensure clinical data privacy. Both models assessed conditions individually or in batches sharing the same patient context, with performance measured against reference labels. In batch mode, JEV and Qwen achieved similar macro-F1 scores on TrialGPT (0.652 vs. 0.660) and MIMIC-IV (0.807 vs. 0.814), whereas JEV substantially outperformed Qwen on MIMIC-III (0.768 vs. 0.534; $Δ$ = +0.234, 95% CI: 0.187-0.281). This advantage largely reflected higher recall for conditions labeled as having insufficient information (56.3% vs. 9.9%). Across all three datasets, JEV also had lower observed median job latency (1.18-1.40 vs. 2.80-8.90 s) and 53%-74% lower estimated cost per condition. These findings position JEV as an initial assessment component that provides criterion-level judgments and flags potential information gaps for review. JEV's observed errors in interpreting clinical evidence underscore the need to verify its outputs against patient records before they inform eligibility decisions.

0.29